Posts filtered by tags: Allergan[x]


 

U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe.
Tags: Money, businessNews, Allergan, U S Supreme Court, Allergan Plc


Health Canada plans to suspend Allergan's breast implant license

(Reuters) - The Canadian health regulator said on Thursday it was advising Allergan Plc that it plans to suspend the license for the Botox-maker's Biocell breast implants. Health Canada said its move followed the completion of its assessment of textured breast implants as part of a larger ongoing safety review. (Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel)
Tags: Science, Canada, Allergan, Bengaluru, Reuters, Health Canada, Allergan Plc, Biocell, Manas Mishra


VC-backed Mirum Pharmaceuticals names Chris Peetz as CEO

Venture-backed Mirum Pharmaceuticals named Chris Peetz as chief executive officer, stepping in for former CEO Mike Grey, who will be in the role of executive chairman of the board. Mirum is backed by investors including NEA, Deerfield Management, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital. Press Release Mirum Pharmaceuticals today announced the appointment of Chris Peetz as chief executive officer. The company’s former CEO, Mik...
Tags: Trends, People, Allergan, St Louis, Chris, Mike, Nash, Washington University, Mirum, Mike Grey, Tobira Therapeutics, Chris Peetz, Jennerex Biotherapeutics Onyx Pharmaceuticals, PFIC, Mirum Pharmaceuticals, ALGS


Regulators just approved the first new depression drug since the 1980s, and some see blockbuster potential (JNJ)

On Tuesday, a drug inspired by ketamine and made by Johnson & Johnson became the first new depression drug in 35 years. Regulators approved the drug, a nasal spray called Spravato or esketamine. The approval comes on the heels of a favorable vote from experts last month who evaluated the drug's safety and effectiveness. The list price of Spravato ranges from $590 to $885 per treatment session, depending on the dose a patient needs. Several biotechs have novel antidepressants in the pipeline,...
Tags: US, Trends, Ubs, Fda, Allergan, Johnson Johnson, J J, Fairview Health Services, US Food and Drug Administration FDA, Steven Meisel, Carter Gould, Spravato, Tiffany Farchione, Farchione


Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that treatment to market, if its final clinical tests are a success.Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey...
Tags: Deals, Startups, New York, Trends, Vc, Allergan, Shire, New Enterprise Associates, Life Sciences, Ophthotech, Princeton NJ, Versant Ventures, National blog main, New York blog main, New York top stories, Seattle blog main


J&J and Allergan are racing to shake up the $9 billion market for depression treatments for the first time in decades (JNJ, SAGE, AGN)

Johnson & Johnson, Allergan, and Sage are racing to launch the first new   depression drugs in 35 years. Cheered by a recent regulatory nod for a new drug called esketamine, analysts are hopeful that other biotechs with novel antidepressants in their pipelines could follow their path. There are more than 16 million adults in the US with depression, and current drugs don't work for roughly a third of them. All existing antidepressants work in roughly the same way, but the new drugs take unconve...
Tags: Boston, US, Trends, Cambridge, Ubs, Fda, Allergan, Business Insider, Cohen, Johnson Johnson, US Food and Drug Administration, US Japan, Stifel, Sage Therapeutics, Mizuho Securities, Paul Matteis


The competition's heating up over a $35 billion market to treat NASH, a 'silent disease' millions are living with. But the early results look mixed.

NASH, short for nonalcoholic steatohepatitis, is a type of liver disease in which liver fat builds up in people. It affects an estimated 16 million Americans, but many don't know it until it leads to more serious problems like liver failure and cirrhosis.  Drugmakers are looking at different ways to treat the condition — both early and later as the disease progresses. Some are conducting research to better understand the genetics and other factors associated with NASH. In February, Gilead said...
Tags: China, US, Trends, Earth, Pfizer, Allergan, Jefferies, Business Insider, Trump, Reuters, Nash, Friedman, RBC Capital Markets, Icahn School of Medicine, Gilead, Regeneron


The competition's heating up over a $35 billion market to treat NASH, a 'silent disease' millions are living with. But some of the early results don't look promising.

NASH, short for nonalcoholic steatohepatitis, is a type of liver disease in which liver fat builds up in people. It affects an estimated 16 million Americans, but many don't know it until it leads to more serious problems like liver failure and cirrhosis.  Drugmakers are looking at different ways to treat the condition — both early and later as the disease progresses. Some are conducting research to better understand the genetics and other factors associated with NASH. On Monday, Gilead said t...
Tags: US, Trends, Pfizer, Allergan, Business Insider, Trump, Reuters, Nash, Friedman, RBC Capital Markets, Icahn School of Medicine, Gilead, Regeneron, Birnbaum, Alnylam, Scott Friedman


Appaloosa steps up pressure on Allergan to split chairman, CEO roles

Hedge fund Appaloosa LP on Tuesday urged pharmaceutical company Allergan PLC to split its chairman and chief executive roles, arguing that an independent chair could help boost the company's sagging share price. Appaloosa's billionaire founder David Tepper turned up the heat on the maker of Botox one week after the company delivered disappointing earnings and shelved plans to sell its women's health business, which it had put on the block in May. "In the wake of last Tuesday's earnings call ...
Tags: Science, Allergan, Allergan Plc, David Tepper, Tepper, Appaloosa, Appaloosa LP


Appaloosa renews call to separate chairman, CEO roles at Allergan

The David Tepper-led hedge fund has a 0.59 percent stake in the drugmaker, according to Refinitiv data. Last week, Allergan shelved plans to sell its women's health business, which it had put on the block in May along with its infectious disease unit to focus on its core businesses. Analysts have said that Allergan is ripe for reentry of shareholder activism following a disappointing earnings report last week.
Tags: Science, Allergan, David Tepper, Appaloosa


FDA approves cheaper Botox rival to treat frown lines

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7) By Manas Mishra (Reuters) - An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent after the bell. The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufactur...
Tags: News, Fda, Allergan, Jeuveau, David Moatazedi, Manas Mishra Reuters, Evolus Inc


Man suspected of killing Irvine father at Malibu Creek State Park is set to answer charges

VAN NUYS — A man accused of killing a research scientist who was camping with his two young daughters last June in Malibu Creek State Park is set to be arraigned Tuesday on murder and other charges. Anthony Rauda, 42, is set to appear in a Van Nuys courtroom and be arraigned on one count of murder, along with 10 counts of attempted murder and five counts of second-degree commercial burglary. The murder charge stems from the shooting death of Irvine resident Tristan Thomas Beaudette while the 35-...
Tags: News, Shooting, La, Tesla, Sport, Soccer, Homicide, Allergan, Local News, Los Angeles County, Irvine, Palmdale, Van Nuys, Calabasas, Los Angeles County Sheriff s Department, Tristan


Man suspected of killing Irvine scientist at Malibu Creek State Park is set to answer charges

Los Angeles County Sheriff’s Department officials shared this image of the arrest of Anthony Rauda, 42, in Malibu Creek State Park on Oct. 10, 2018. Detectives believe Rauda, a parolee with a history of weapons violations, is the suspect in a string of burglaries in Calabasas and unincorporated areas around the wilderness park. (Josh Cain/SCNG staff) VAN NUYS — A man accused of killing a research scientist who was camping with his two young daughters last June in Malibu Creek State Park is set...
Tags: News, Shooting, La, Tesla, Sport, Soccer, Homicide, Allergan, Local News, Los Angeles County, Irvine, Palmdale, Van Nuys, Calabasas, Los Angeles County Sheriff s Department, Tristan


Allergan, Saint Regis Mohawk Tribe Ask SCOTUS To Hear Restasis Patent Case

A federal court last year put the kibosh on a deal whereby Allergan transferred to the tribe the Restasis patents, which the tribe then licensed back to Allergan, asserting tribal sovereign immunity to have generic companies' challenge to the patents dismissed.
Tags: Law, Courts, Allergan, Restasis


Health Canada places restrictions on Allergan's fibroid treatment Esmya

Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug. Health Canada said the drug, sold under brand name Fibristal in the country, should not be used by women with liver problems, or those who have had such problems in the past. It also said that more than one treatment course of the drug should be restricted to only those of childbearing age who are unable to undergo...
Tags: Science, Canada, Allergan, Health Canada, Allergan Plc


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders


India: A Tale Of Restasis: Misadventures Of Sovereign Immunity - Khurana and Khurana

Allergan's "Restasis®" is a branded ophthalmic cyclosporine emulsion, for the treatment of chronic dry eye, with annual sales of nearly $1.5 billion.
Tags: News, India, Allergan, Khurana


A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.

Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide. Current treatments all work in the same way, and haven't changed significantly in 35 years. Plus, they don't help as many as 1 in 3 patients. Some new drug candidates draw inspiration from psychedelics like hallucinogenic mushrooms and ketamine. Another works on a brain network called Gaba that other medications ignore. As many as one in every three people with depression does not get re...
Tags: Trends, Nasa, Peter Thiel, Silicon Valley, Columbia University, Fda, Allergan, Mars, Imperial College London, Business Insider, Johnson Johnson, Stifel, Mike Novogratz, David Nutt, GABA, Paul Matteis


Why FedEx, Allergan, and FTS International Slumped Today

Find out which stocks fell on an important day for monetary policy.
Tags: Finance, Article, Allergan, FBN, Motley Fool, Fbn/markets, Fox-business/markets, 39b6f97c-23b1-5b88-8563-9127861a2ffe


Allergan stops sale of textured breast implants in Europe, shares sink

Allergan defended the safety of its breast implants, but its shares fell 7.4 percent to $135.94 on Wednesday as some Wall Street analysts questioned whether the company would have to face any future product liability costs. France's National Agency for the Safety of Medicines & Health Products (ANSM) said late on Tuesday that it was recalling Allergan's Microcell and Biocell textured breast implants because its safety certification had not been renewed by another agency. Textured breast implan...
Tags: Europe, Science, France, United States, Allergan, MICROCELL, Safety of Medicines Health Products ANSM


Allergan stops sales of textured breast implants in Europe

Drugmaker Allergan said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered the recall of the implants, which have been linked to a rare form of cancer. France's National Agency for the Safety of Medicines & Health Products (ANSM) said late Tuesday that the decision concerned Allergan's Microcell and Biocell textured breast implants. Allergan shares fell 4.5 percent in early trading.
Tags: Europe, Science, France, Allergan, MICROCELL, Biocell, Safety of Medicines Health Products ANSM


Breast implants linked to cancer withdrawn from sale in Europe

French authorities withdrew approval for Allergan textured implants, popular in UKBreast implants that have been linked to a rare form of cancer have been pulled from the market in Europe.The recall of Allergan textured implants, one of the most popular types in the UK, came after French authorities announced they had withdrawn approval for their sale in Europe. Continue reading...
Tags: Health, Europe, UK, France, Cancer, European Union, Society, World news, Allergan


Allergan stops sales in Europe of breast implants linked to cancer

The decision concerned Allergan's Microcell and Biocell products.
Tags: Europe, Finance, Article, Allergan, Reuters, FBN, Fbn/markets, Fox-business/markets, MICROCELL, 32fe164b-14e7-5af1-b962-91a378c188c2


With $42M, Ex-Ignyta CEO Aims At Cancer Again With Startup, Erasca

A year after steering cancer drug developer Ignyta into a $1.7 billion sale to Roche, Jonathan Lim is back at it again. Ignyta’s former co-founder and head executive has co-founded another biotech in San Diego, Erasca, which also wants to make new cancer therapies.Erasca on Tuesday closed a $42 million Series A round led by Lim’s own investment firm, City Hill Ventures, and Boston-based Cormorant Asset Management. Other, unnamed institutional and individual investors also participated. The comp...
Tags: Deals, Startups, Drugs, Entrepreneurship, Boston, Cancer, Trends, Vc, Autoimmune, Stem Cells, Venture Capital, San Diego, Botox, Allergan, Biotech, Life Sciences


Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer

The company’s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma.
Tags: Europe, News, France, Cancer, Plastic Surgery, Allergan, Breasts, Medical Devices, Implants, Allergan Inc, Recalls and Bans of Products, Non-Hodgkin's Lymphoma


Studio City woman claims Pasadena plastic surgeon ‘experimented’ on her and altered medical records to hide it

If money was her only goal, Wendy Knecht could have walked away when she settled her lawsuit against a Pasadena plastic surgeon for $1 million. Instead, the Studio City woman is taking her case to the state, encouraging authorities to prosecute Dr. Max Lehfeldt’s for altering her medical records after she sued the physician for using an experimental device in her breast reconstruction. Knecht claimed in her 2016 suit that she was left disfigured and forced to undergo three additional surgeries t...
Tags: Health, News, California, Sport, Hospital, Soccer, Fda, Allergan, Pasadena, Los Angeles Times, Arcadia, American Bar Association, Morgan, U S Food and Drug Administration, Sutton, Centers for Medicare


To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health

Synergy Pharmaceuticals has spent years looking for a buyer. The developer of a struggling drug for two types of chronic constipation finally has one—now that it’s gone bankrupt.New York-based Synergy (NASDAQ SGYP) cut a deal on Wednesday to sell itself to Bausch Health, a Canadian specialty pharma company, for roughly $200 million in cash. The deal is subject to an auction that will be carried out through a Chapter 11 bankruptcy filing, which allows businesses to reorganize their finances or s...
Tags: Deals, New York, Drugs, Trends, Bankruptcy, Allergan, Biotech, Life Sciences, Chapter 11, Vanguard Group, Bausch, National blog main, New York blog main, New York top stories, Boston blog main, Boston top stories


Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash


A 'party drug' with potential to be the next blockbuster antidepressant is edging closer to the mainstream, but it could set you back $9,000

Once dismissed as a "party drug," ketamine is emerging as a potential alternative treatment for depression. A growing list of academic medical centers now offer the drug, including Columbia University, which began offering ketamine to patients with severe depression this fall. Ketamine works differently from common antidepressants like Celexa or Prozac and has been called "the most important discovery in half a century." Pharmaceutical companies, including Allergan and Johnson & Johnson, are a...
Tags: New York, California, Kaiser Permanente, US, San Francisco, Trends, Harvard University, San Diego, Kaiser, Columbia University, Fda, Allergan, Ketamine, Columbia, Business Insider, Mount Sinai


A ‘party drug’ with potential to be the next blockbuster antidepressant is edging closer to the mainstream, but it could set you back $9,000

Once dismissed as a "party drug," ketamine is emerging as a potential alternative treatment for depression. A growing list of academic medical centers now offer the drug, including Columbia University, which began offering ketamine to patients with severe depression this fall. Ketamine works differently from common antidepressants like Celexa or Prozac and has been called "the most important discovery in half a century." Pharmaceutical companies including Allergan and Johnson & Johnson are als...
Tags: New York, California, Kaiser Permanente, US, San Francisco, Trends, Harvard University, San Diego, Kaiser, Columbia University, Fda, Allergan, Ketamine, Columbia, Business Insider, Mount Sinai